↓ Skip to main content

Effective treatment of spasticity using dronabinol in pediatric palliative care

Overview of attention for article published in European Journal of Paediatric Neurology, November 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
4 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
97 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effective treatment of spasticity using dronabinol in pediatric palliative care
Published in
European Journal of Paediatric Neurology, November 2016
DOI 10.1016/j.ejpn.2016.07.021
Pubmed ID
Authors

Michaela Kuhlen, Jessica I. Hoell, Gabriele Gagnon, Stefan Balzer, Prasad T. Oommen, Arndt Borkhardt, Gisela Janßen

Abstract

Cannabis extracts have a wide therapeutic potential but in many countries they have not been approved for treatment in children so far. We conducted an open, uncontrolled, retrospective study on the administration of dronabinol to determine the value, efficacy, and safety of cannabis-based medicines in the treatment of refractory spasticity in pediatric palliative care. Sixteen children, adolescents and young adults having complex neurological conditions with spasticity (aged 1.3-26.6 years, median 12.7 years) were treated with dronabinol by our specialized pediatric palliative care team between 01.12.2010 and 30.04.2015 in a home-care setting. Therapeutic efficacy and side effects were closely monitored. Drops of the 2.5% oily tetrahydrocannabinol solution (dronabinol) were administered. A promising therapeutic effect was seen, mostly due to abolishment or marked improvement of severe, treatment resistant spasticity (n = 12). In two cases the effect could not be determined, two patients did not benefit. The median duration of treatment was 181 days (range 23-1429 days). Dosages to obtain a therapeutic effect varied from 0.08 to 1.0 mg/kg/d with a median of 0.33 mg/kg/d in patients with a documented therapeutic effect. When administered as an escalating dosage scheme, side effects were rare and only consisted in vomiting and restlessness (one patient each). No serious and enduring side effects occurred even in young children and/or over a longer period of time. In the majority of pediatric palliative patients the treatment with dronabinol showed promising effects in treatment resistant spasticity.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 97 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 13%
Student > Bachelor 12 12%
Other 10 10%
Student > Master 9 9%
Student > Doctoral Student 7 7%
Other 21 22%
Unknown 25 26%
Readers by discipline Count As %
Medicine and Dentistry 36 37%
Nursing and Health Professions 9 9%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Neuroscience 2 2%
Biochemistry, Genetics and Molecular Biology 2 2%
Other 12 12%
Unknown 30 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2016.
All research outputs
#6,400,282
of 12,357,782 outputs
Outputs from European Journal of Paediatric Neurology
#188
of 664 outputs
Outputs of similar age
#100,600
of 267,375 outputs
Outputs of similar age from European Journal of Paediatric Neurology
#7
of 72 outputs
Altmetric has tracked 12,357,782 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 664 research outputs from this source. They receive a mean Attention Score of 2.8. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,375 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.